A Winter Connection Event

Even Though We Are Apart
We Are Still Together
Although we can’t be together in person, we are reaching out to you with a special package.
We want to use this opportunity to show you that we’re still thinking about you during these challenging times.
To receive this FREE PACKAGE register for the MSCDA Winter Connection!
Please REGISTER BY DECEMBER 7, 2021 (Eligible for residents of Maryland, D.C., and Northern Virginia only)
Questions? Email mscdainfo@verizon.net or call Petronella Barrow at 667-786-1853.
Register Now:
Fill out my online form.
This Program Was Supported By:
GBT-sized
terumo-sized
medunik-sized
SC

Share this post

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."